Capstone Investment Advisors
FDMT icon

Capstone Investment Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

Capstone Investment Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-22,917
Closed -$199K – 1754
2025
Q3 		$199K Buy
+22,917
New +$137K ﹤0.01% 1840
2024
Q3 		– Sell
-9,548
Closed -$200K – 2007
2024
Q2 		$200K Buy
+9,548
New +$240K ﹤0.01% 1768
2021
Q2 		– Sell
-5,879
Closed -$255K – 1763
2021
Q1 		$255K Buy
+5,879
New +$260K ﹤0.01% 1382

Other funds holding FDMT

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Capstone Investment Advisors's FDMT Position: Q4 2025 in Review

Capstone Investment Advisors sold out of 4D Molecular Therapeutics (FDMT) in Q4 2025, closing a stake of 22,917 shares — an estimated $199K sold.

Capstone Investment Advisors first reported a position in FDMT in Q1 2021 and held it in 3 quarters. The position peaked at $255K in Q1 2021. 153 funds tracked by Wall St. Rank hold FDMT as of Q4 2025.

  • Capstone Investment Advisors reported no remaining 4D Molecular Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Capstone Investment Advisors sold 22,917 4D Molecular Therapeutics shares in Q4 2025, an estimated $199K.
  • Capstone Investment Advisors first reported a position in 4D Molecular Therapeutics in Q1 2021 and held it in 3 quarters.
  • Capstone Investment Advisors's 4D Molecular Therapeutics position peaked at $255K in Q1 2021.
  • 153 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2025.

Based on Capstone Investment Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.